chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 37.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Drug ineffective, SARS-CoV-2 test
Clinical narrative: COVID 19; Drug ineffective; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 38-year-old male patient received BNT162b2 (BNT162B2), on 23Nov2021 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 37 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported. Past drug history included: Amoxicillan, reaction(s): "Allergy". The following information was reported: COVID-19 (medically significant), outcome "unknown", described as "COVID 19"; DRUG INEFFECTIVE (medically significant), outcome "unknown".  The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (29Jun2022) negative; (30Jun2022) Positive; (03Jul2022) Still Positive. Tested positive after testing negative. No symptoms since 24Jun2022. Therapeutic measures were taken as a result of covid-19, drug ineffective. The patient used Paxlovid from 21Jun2022 to 26Jun2022 as treatment of COVID-19. Other medication details: ibuprofen and acetaminophen both from 21Jun2022 to 23Jun2022.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Drug ineffective, SARS-CoV-2 antibody test
Clinical narrative: Caught COVID; Caught COVID; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 45-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 22Oct2021 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 45 years for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Tree nuts" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 05May2022, outcome "not recovered" and all described as "Caught COVID". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 antibody test: Unknown results, notes: Caught COVID again 8 weeks later. Therapeutic measures were taken as a result of drug ineffective, covid-19.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Sex: F
Vaccine: COVID19
Symptoms: Cardiomyopathy, Chronic obstructive pulmonary disease, Pneumonectomy
Clinical narrative: Cardiomyopathy; COPD; I had half my lung removed; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team, Program ID. The reporter is the patient.  A 61-year-old female patient received BNT162b2 (BNT162B2), in Feb2021 as dose 1, single (Batch/Lot number: unknown), in Mar2021 as dose 2, single (Batch/Lot number: unknown) and in Aug2021 as dose 3 (booster), single (Batch/Lot number: unknown) for COVID-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PNEUMONECTOMY (medically significant) with onset 2021, outcome "unknown", described as "I had half my lung removed"; CARDIOMYOPATHY (medically significant), outcome "unknown"; CHRONIC OBSTRUCTIVE PULMONARY DISEASE (non-serious), outcome "unknown", described as "COPD". Therapeutic measures were taken as a result of cardiomyopathy and included Defibrulator (CRT-D) implantation; pneumonectomy was a therapeutic measure taken as a result of its cause (pending clarification). Clinical course: Patient stated, "I had half my lung removed last year and also have COPD well as Cardiomyopathy and a Defibrulator (CRT-D) implanted. I am age 61 and retired." Patient received 1st dose in mid February in 2021, 2nd dose in late March in 2021, Booster 1 in late August in 2021, Booster 2 in early February in 2022. Patient also stated, "It has been 5 months since my 2nd booster. Are 3rd BOOSTERS (5th shot) in the works for APPROVAL of the Pfizer vaccine for those who are immunocompromised like myself?" "Serious: No" was also reported.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective, SARS-CoV-2 test
Clinical narrative: the patient had COVID; the patient had COVID; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 56-year-old female patient received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and in Sep2021 as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "immunosuppressed" (ongoing); "collagen disease not identified" (ongoing). Concomitant medication(s) included: METHOTREXATE taken for collagen disorder. The patient was immunosuppressed with methotrexate because she had a medical condition (collagen disease not identified). The following information was reported: DRUG INEFFECTIVE (medically significant) with onset 18Jun2022, outcome "not recovered", described as "the patient had COVID"; COVID-19 (medically significant) with onset 18Jun2022, outcome "not recovered", described as "the patient had COVID ". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (2022) Positive. The patient's test continued positive until time of report.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Age: 59.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Drug ineffective, SARS-CoV-2 test
Clinical narrative: COVID 19; COVID 19; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 59-year-old female patient received BNT162b2 (BNT162B2), on 09Apr2022 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 59 years for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history was not reported. No known allergies. Concomitant medication(s) included: SYNTHROID; OZEMPIC. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "COVID 19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: Positive antigen test on day 3 after initial negative test (day 10 of first having symptoms); negative, notes: Positive antigen test on day 3 after initial negative test (day 10 of first having symptoms). The patient received Paxlovid as treatment of COVID-19 from 23Jun2022 to 27Jun2022. No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Sex: U
Vaccine: COVID19
Symptoms: Drug ineffective, SARS-CoV-2 test, Suspected COVID-19
Clinical narrative: I've had four Pfizer vaccinations, Covid, and now Paxlovid/ I'm frustrated they aren't better.; I've had four Pfizer vaccinations, Covid, and now Paxlovid; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP), Program ID:. The reporter is the patient.  A patient (no qualifiers provided) received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown), as dose 3 (booster), single (Batch/Lot number: unknown) and as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), outcome "unknown", described as "I've had four Pfizer vaccinations, Covid, and now Paxlovid/ I'm frustrated they aren't better."; SUSPECTED COVID-19 (medically significant), outcome "unknown", described as "I've had four Pfizer vaccinations, Covid, and now Paxlovid". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Unknown results. Therapeutic measures were taken as a result of drug ineffective, suspected covid-19. It was reported that patient four Pfizer vaccinations, Covid, and now Paxlovid, and it's a horrible journey.  Patient was grateful the medications exist but patient was frustrated they aren't better.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Age: 58.0
Sex: F
Vaccine: COVID19, UNK
Symptoms: COVID-19, Drug ineffective, SARS-CoV-2 test
Clinical narrative: COVID-19; COVID-19; This is a solicited report received from non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. Other Case identifier(s): 22K-163-4259395-00.  A 58-year-old female patient received BNT162b2 (BNT162B2), on 03Mar2021 as dose 1, single (Batch/Lot number: unknown) and on 26Apr2021 as dose 2, single (Batch/Lot number: unknown),on 26Oct2021 as dose 3, single (Batch/Lot number: unknown)  at the age of 58 years, all intramuscular for covid-19 immunisation; adalimumab (HUMIRA), (Batch/Lot number: unknown), subcutaneous for psoriasis,Daily dose: Citrate free. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: COVID-19 (medically significant) with onset 01Oct2021, outcome "recovered" (Jun2022), DRUG INEFFECTIVE (medically significant) with onset 01Oct2021, outcome "unknown" and all described as "COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (01Oct2022) Positive. The action taken for adalimumab was unknown.  The reporter considered "covid-19" related to BNT162b2.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: The vaccine efficacy varies from one patient to another and can be affected by different factors; however, a contributory role of the suspect vaccine BNT162B2 to the drug ineffective (LOE) and COVID-19 cannot be ruled out.
Sex: U
Vaccine: COVID19
Symptoms: Myelin oligodendrocyte glycoprotein antibody-associated disease, Myelitis transverse
Clinical narrative: Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease; Transverse Myelitis; This is a literature report.  A patient (no qualifiers provided) received COVID-19 Vaccine - Manufacturer Unknown, as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported.  The following information was reported: MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (medically significant), outcome "unknown"; MYELITIS TRANSVERSE (medically significant), outcome "unknown", described as "Transverse Myelitis".; Sender's Comments: As there is limited information in the case provided, the causal association between the reported events and the suspect drug cannot be excluded. The case will be reassessed once new information is available.   The impact of this report on the benefit/risk profile of the Pfizer drug is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees, and Investigators, as appropriate.,Linked Report(s) : US-PFIZER INC-202200916772 Same drug and different event/patient;
Sex: U
Vaccine: COVID19
Symptoms: Blood cholesterol, Blood test, Cardiac monitoring, Electrocardiogram, Laboratory test
Clinical narrative: This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP), Program ID: The reporter is the patient. A patient (no qualifiers provided) received BNT162b2 (BNT162B2), on 19Apr2022 as dose number unknown (booster), single (Batch/Lot number: unknown) for covid-19 immunization. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Primary Immunization series complete, Unknown Manufacturer), for COVID-19 Immunization. The following information was reported: VISUAL IMPAIRMENT (non-serious) with onset 24Apr2022, outcome "recovered" (24Apr2022), described as "my right eye went half blind/The right side of my right eye was dark/black". Relevant laboratory tests and procedures are available in the appropriate section. Additional information: The reporter reported that, I received my 1st Booster on 19Apr2022 five days after my right eye went half blind. The right side of my right eye was dark/black. This lasted about 1.5 hours. I told my doctor he ran blood work, Magnetic resonance imaging (MRI) on my brain, I wore a heart monitor for 3 days, electrocardiogram(EKG) and I had to see an ophthalmologist. The only negative was my cholesterol all other tests showed nothing. Ophthalmologist ran tests too with everything ok. I talked with many people regarding this incident many have had some the similar reaction. The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Sex: U
Vaccine: COVID19
Symptoms: Magnetic resonance imaging head, Visual impairment
Clinical narrative: This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP), Program ID: The reporter is the patient. A patient (no qualifiers provided) received BNT162b2 (BNT162B2), on 19Apr2022 as dose number unknown (booster), single (Batch/Lot number: unknown) for covid-19 immunization. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Primary Immunization series complete, Unknown Manufacturer), for COVID-19 Immunization. The following information was reported: VISUAL IMPAIRMENT (non-serious) with onset 24Apr2022, outcome "recovered" (24Apr2022), described as "my right eye went half blind/The right side of my right eye was dark/black". Relevant laboratory tests and procedures are available in the appropriate section. Additional information: The reporter reported that, I received my 1st Booster on 19Apr2022 five days after my right eye went half blind. The right side of my right eye was dark/black. This lasted about 1.5 hours. I told my doctor he ran blood work, Magnetic resonance imaging (MRI) on my brain, I wore a heart monitor for 3 days, electrocardiogram(EKG) and I had to see an ophthalmologist. The only negative was my cholesterol all other tests showed nothing. Ophthalmologist ran tests too with everything ok. I talked with many people regarding this incident many have had some the similar reaction. The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Sex: M
Vaccine: COVID19
Symptoms: Cerebrovascular accident
Clinical narrative: Stroke; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. Other Case identifier(s): NVSC2022US067671_OS (Novartis Pharmaceuticals Corporation).  A 75-year-old male patient received BNT162b2 (BNT162B2), as dose number unknown (booster), single (Batch/Lot number: unknown) for covid-19 immunization. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Primary immunization series completed. Unknown manufacturer.), for COVID-19 immunization. The following information was reported: CEREBROVASCULAR ACCIDENT (medically significant), outcome "unknown", described as "Stroke". Clinical course was reported as, Patient stated that he had the COVID-19 booster vaccine and had a stroke.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Age: 20.0
Sex: F
Vaccine: MNQ
Symptoms: Axillary pain, Condition aggravated
Clinical narrative: pain in my left armpit; pain has been worse on Wednesday than it was on Tuesday.; Initial information received on 30-Jun-2022 regarding an unsolicited valid non-serious case received from a consumer/non- health care professional.  This case involves a 20 years old female patient who experienced pain in my left armpit after receiving vaccine Meningococcal A-C-Y-W135 (D Conj) Vaccine [Menactra].  The patient's past medical history, medical treatment(s), vaccination(s), concomitant medication(s) and family history were not provided.   On 27-Jun-2022, the patient received a 0.5 ml dose (total) of suspect meningococcal a-c-y-w135 (d conj) vaccine Solution for injection (strength, frequency, batch lot number and expiry date: unknown) via intramuscular route in the left arm as prophylactic vaccination (immunization).  On 28-JUN-2022 the patient developed a non-serious event pain in my left armpit (axillary pain) with symptom pain has been worse on wednesday than it was on tuesday (pain) latency: 1 day following the administration of meningococcal a-c-y-w135 (d conj) vaccine.  It was reported that the patient has been experiencing pain in her left armpit on Tuesday June 28th, 2022, and Wednesday June29th 2022 after receiving the Menactra vaccination on Monday June27th 2022. The pain can be described as stabbing and aching.  It is unknown if there were lab data/results available.  Action taken was not applicable.  It was not reported if the patient received a corrective treatment for the events (axillary pain).  At time of reporting, the outcome was Unknown for the event axillary pain.
Age: 1.0
Sex: F
Vaccine: DTAPIPVHIB, HIBV
Symptoms: Extra dose administered
Clinical narrative: received a dose of Pentacel and PedvaxHIB on the same day, which resulted in an extra dose of the HIB component for the patient with no reported adverse event; Initial information received on 27-Jun-2022 regarding an unsolicited valid  non-serious case received from a other health professional.  This case involves a 1 years old female patient who had received a dose of pentacel and pedvaxhib on the same day, which resulted in an extra dose of the hib component for the patient with no reported adverse event while receiving vaccines PEDVAXHIB and DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE [PENTACEL].  The patient's past medical history, medical treatment(s), concomitant medication, vaccination(s) and family history were not provided.   On 23-Jun-2022, the patient received 0.5ml dose of suspect DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE (strength, formulation was unknown, lot UJ529AAA and expiry date: 22-Jul-2022) via intramuscular route in unknown administration site for Immunization. On an unknown date, the patient received an unknown dose of suspect PEDVAXHIB not produced by Sanofi Pasteur (strength, formulation was unknown, lot UJ529AAAo and expiry date was unknown) via unknown route in unknown administration site for Prophylactic vaccination.  On 23-Jun-2022 the patient developed a non-serious event received a dose of pentacel and pedvaxhib on the same day, which resulted in an extra dose of the hib component for the patient with no reported adverse event (extra dose administered) following the administration of DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE and (latency: unknown) following the administration of PEDVAXHIB.  Action taken : not applicable.  Outcome: Unknown  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 56.0
Sex: M
Vaccine: COVID19
Symptoms: Aspiration, Rhinorrhoea
Clinical narrative: Constant nasal drainage.  Very low rate.  24 hours a day.  Was not noticeable initially.  Now noticeable daily, especially daily when awaking, and when builds up causing aspiration at different times of the day.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Chest pain, SARS-CoV-2 test positive
Clinical narrative: 6/21 37y.o. female with a PMH significant for hypertension and generalized anxiety disorder. Who presented from home with a chief complaint of chest pain of 1 day duration
Age: 52.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Acoustic stimulation tests, Disturbance in attention, Ear, nose and throat examination, Impaired work ability, Loss of personal independence in daily activities
Clinical narrative: After receiving the 3rd dose of Pfizer Booster, Starting about a week later I have been experiencing debilitating Tinnitus - Ringing in my ears, I have never suffered from Tinnitus ever. And have been waiting for months, hoping it would go away, It affects me every day, affects my sleep, my concentration, affects my work and personal life!!! I have been seeking medical attention but am being told there is no cure and nothing that can be done to help with this condition. I strongly feel this is caused by the Pfizer injections that I received.
Age: 52.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Sleep disorder, Tinnitus
Clinical narrative: After receiving the 3rd dose of Pfizer Booster, Starting about a week later I have been experiencing debilitating Tinnitus - Ringing in my ears, I have never suffered from Tinnitus ever. And have been waiting for months, hoping it would go away, It affects me every day, affects my sleep, my concentration, affects my work and personal life!!! I have been seeking medical attention but am being told there is no cure and nothing that can be done to help with this condition. I strongly feel this is caused by the Pfizer injections that I received.
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: Acute myocardial infarction, Anaemia, Angiogram peripheral normal, Anticoagulant therapy, Arteriogram coronary abnormal
Clinical narrative: Pfizer Dose 1 3/8/21 (EN6199) Pfizer Dose 2 4/7/21 (ER8737) Pfizer Dose 3 10/21/21 (FF2593) COVID Positive 1/11/22 COVID Positive 1/24/22  1/24/22: Patient is a 81 year old male who presented to ED via EMS with complaints of chest pain while shoveling snow just prior to arrival. He took 2 sublingual nitro with no relief in symptoms and called EMS. Chest pain was left sided, non-radiating, sharp and constant in nature, no alleviating or aggravating factors. Denies shortness of breath. No diaphoresis, nausea, or vomiting. Chest pain relieved in ED. He is fully vaccinated for Covid-19. Past has a past medical history of hypertension, hyperlipidemia, hypothyroidism, CAD s/p CABG and multiple stents, type 2 diabetes mellitus, seizure disorder, pvd s/p stent, anemia, right lower extremity DVT on Coumadin and history of cva.  On arrival to ED pt was hypertensive 165/65. Labs significant for hyperglycemia 266. Hypomagnesemia 1.3. D-dimer 0.65. CT chest no PE. Chest xray unremarkable. No trop leak. EKG sinus rhythm with RBBB, rate 78, QTC 437. 4 baby aspirin and sublingual nitro given in ED with relief in chest pain.  1/29/22: 81-year-old male with coronary artery disease status post CABG and PCIs, peripheral vascular disease status post intervention presented with left-sided chest pain while shoveling snow, improved with sublingual nitroglycerin in the emergency room.  Patient elevated troponin with no ischemic EKG changes.  Patient admitted for non STEMI, started on heparin GTT Cardiology was consulted patient underwent coronary angiogram with the intervention including stents.  Patient retroperitoneal hemorrhage following the procedure, hypotensive and anemic requiring blood transfusion.  Peripheral angiogram did not reveal pseudoaneurysm or extravasation.  Hemoglobin remained stable.  Patient was supposed to be on warfarin for DVT, repeat lower extremity ultrasound showed no deep vein thrombosis and in the setting of retroperitoneal hemorrhage with anemia, dual anti-platelet it was deemed patient is at significant risk for bleeding and anticoagulation discontinued.  Patient had recurrence of symptoms IVC filter can be considered as an outpatient.  On discharge patient was afebrile and hemodynamically stable he was discharged home.
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: Bundle branch block right, COVID-19, Chest X-ray normal, Chest pain, Computerised tomogram thorax normal
Clinical narrative: Pfizer Dose 1 3/8/21 (EN6199) Pfizer Dose 2 4/7/21 (ER8737) Pfizer Dose 3 10/21/21 (FF2593) COVID Positive 1/11/22 COVID Positive 1/24/22  1/24/22: Patient is a 81 year old male who presented to ED via EMS with complaints of chest pain while shoveling snow just prior to arrival. He took 2 sublingual nitro with no relief in symptoms and called EMS. Chest pain was left sided, non-radiating, sharp and constant in nature, no alleviating or aggravating factors. Denies shortness of breath. No diaphoresis, nausea, or vomiting. Chest pain relieved in ED. He is fully vaccinated for Covid-19. Past has a past medical history of hypertension, hyperlipidemia, hypothyroidism, CAD s/p CABG and multiple stents, type 2 diabetes mellitus, seizure disorder, pvd s/p stent, anemia, right lower extremity DVT on Coumadin and history of cva.  On arrival to ED pt was hypertensive 165/65. Labs significant for hyperglycemia 266. Hypomagnesemia 1.3. D-dimer 0.65. CT chest no PE. Chest xray unremarkable. No trop leak. EKG sinus rhythm with RBBB, rate 78, QTC 437. 4 baby aspirin and sublingual nitro given in ED with relief in chest pain.  1/29/22: 81-year-old male with coronary artery disease status post CABG and PCIs, peripheral vascular disease status post intervention presented with left-sided chest pain while shoveling snow, improved with sublingual nitroglycerin in the emergency room.  Patient elevated troponin with no ischemic EKG changes.  Patient admitted for non STEMI, started on heparin GTT Cardiology was consulted patient underwent coronary angiogram with the intervention including stents.  Patient retroperitoneal hemorrhage following the procedure, hypotensive and anemic requiring blood transfusion.  Peripheral angiogram did not reveal pseudoaneurysm or extravasation.  Hemoglobin remained stable.  Patient was supposed to be on warfarin for DVT, repeat lower extremity ultrasound showed no deep vein thrombosis and in the setting of retroperitoneal hemorrhage with anemia, dual anti-platelet it was deemed patient is at significant risk for bleeding and anticoagulation discontinued.  Patient had recurrence of symptoms IVC filter can be considered as an outpatient.  On discharge patient was afebrile and hemodynamically stable he was discharged home.
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: Condition aggravated, Coronary arterial stent insertion, Electrocardiogram, Electrocardiogram QT interval, Fibrin D dimer
Clinical narrative: Pfizer Dose 1 3/8/21 (EN6199) Pfizer Dose 2 4/7/21 (ER8737) Pfizer Dose 3 10/21/21 (FF2593) COVID Positive 1/11/22 COVID Positive 1/24/22  1/24/22: Patient is a 81 year old male who presented to ED via EMS with complaints of chest pain while shoveling snow just prior to arrival. He took 2 sublingual nitro with no relief in symptoms and called EMS. Chest pain was left sided, non-radiating, sharp and constant in nature, no alleviating or aggravating factors. Denies shortness of breath. No diaphoresis, nausea, or vomiting. Chest pain relieved in ED. He is fully vaccinated for Covid-19. Past has a past medical history of hypertension, hyperlipidemia, hypothyroidism, CAD s/p CABG and multiple stents, type 2 diabetes mellitus, seizure disorder, pvd s/p stent, anemia, right lower extremity DVT on Coumadin and history of cva.  On arrival to ED pt was hypertensive 165/65. Labs significant for hyperglycemia 266. Hypomagnesemia 1.3. D-dimer 0.65. CT chest no PE. Chest xray unremarkable. No trop leak. EKG sinus rhythm with RBBB, rate 78, QTC 437. 4 baby aspirin and sublingual nitro given in ED with relief in chest pain.  1/29/22: 81-year-old male with coronary artery disease status post CABG and PCIs, peripheral vascular disease status post intervention presented with left-sided chest pain while shoveling snow, improved with sublingual nitroglycerin in the emergency room.  Patient elevated troponin with no ischemic EKG changes.  Patient admitted for non STEMI, started on heparin GTT Cardiology was consulted patient underwent coronary angiogram with the intervention including stents.  Patient retroperitoneal hemorrhage following the procedure, hypotensive and anemic requiring blood transfusion.  Peripheral angiogram did not reveal pseudoaneurysm or extravasation.  Hemoglobin remained stable.  Patient was supposed to be on warfarin for DVT, repeat lower extremity ultrasound showed no deep vein thrombosis and in the setting of retroperitoneal hemorrhage with anemia, dual anti-platelet it was deemed patient is at significant risk for bleeding and anticoagulation discontinued.  Patient had recurrence of symptoms IVC filter can be considered as an outpatient.  On discharge patient was afebrile and hemodynamically stable he was discharged home.
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: Haemoglobin normal, Hyperglycaemia, Hypermagnesaemia, Hypertension, Hypotension
Clinical narrative: Pfizer Dose 1 3/8/21 (EN6199) Pfizer Dose 2 4/7/21 (ER8737) Pfizer Dose 3 10/21/21 (FF2593) COVID Positive 1/11/22 COVID Positive 1/24/22  1/24/22: Patient is a 81 year old male who presented to ED via EMS with complaints of chest pain while shoveling snow just prior to arrival. He took 2 sublingual nitro with no relief in symptoms and called EMS. Chest pain was left sided, non-radiating, sharp and constant in nature, no alleviating or aggravating factors. Denies shortness of breath. No diaphoresis, nausea, or vomiting. Chest pain relieved in ED. He is fully vaccinated for Covid-19. Past has a past medical history of hypertension, hyperlipidemia, hypothyroidism, CAD s/p CABG and multiple stents, type 2 diabetes mellitus, seizure disorder, pvd s/p stent, anemia, right lower extremity DVT on Coumadin and history of cva.  On arrival to ED pt was hypertensive 165/65. Labs significant for hyperglycemia 266. Hypomagnesemia 1.3. D-dimer 0.65. CT chest no PE. Chest xray unremarkable. No trop leak. EKG sinus rhythm with RBBB, rate 78, QTC 437. 4 baby aspirin and sublingual nitro given in ED with relief in chest pain.  1/29/22: 81-year-old male with coronary artery disease status post CABG and PCIs, peripheral vascular disease status post intervention presented with left-sided chest pain while shoveling snow, improved with sublingual nitroglycerin in the emergency room.  Patient elevated troponin with no ischemic EKG changes.  Patient admitted for non STEMI, started on heparin GTT Cardiology was consulted patient underwent coronary angiogram with the intervention including stents.  Patient retroperitoneal hemorrhage following the procedure, hypotensive and anemic requiring blood transfusion.  Peripheral angiogram did not reveal pseudoaneurysm or extravasation.  Hemoglobin remained stable.  Patient was supposed to be on warfarin for DVT, repeat lower extremity ultrasound showed no deep vein thrombosis and in the setting of retroperitoneal hemorrhage with anemia, dual anti-platelet it was deemed patient is at significant risk for bleeding and anticoagulation discontinued.  Patient had recurrence of symptoms IVC filter can be considered as an outpatient.  On discharge patient was afebrile and hemodynamically stable he was discharged home.
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration, Retroperitoneal haemorrhage, SARS-CoV-2 test positive, Sinus rhythm, Transfusion
Clinical narrative: Pfizer Dose 1 3/8/21 (EN6199) Pfizer Dose 2 4/7/21 (ER8737) Pfizer Dose 3 10/21/21 (FF2593) COVID Positive 1/11/22 COVID Positive 1/24/22  1/24/22: Patient is a 81 year old male who presented to ED via EMS with complaints of chest pain while shoveling snow just prior to arrival. He took 2 sublingual nitro with no relief in symptoms and called EMS. Chest pain was left sided, non-radiating, sharp and constant in nature, no alleviating or aggravating factors. Denies shortness of breath. No diaphoresis, nausea, or vomiting. Chest pain relieved in ED. He is fully vaccinated for Covid-19. Past has a past medical history of hypertension, hyperlipidemia, hypothyroidism, CAD s/p CABG and multiple stents, type 2 diabetes mellitus, seizure disorder, pvd s/p stent, anemia, right lower extremity DVT on Coumadin and history of cva.  On arrival to ED pt was hypertensive 165/65. Labs significant for hyperglycemia 266. Hypomagnesemia 1.3. D-dimer 0.65. CT chest no PE. Chest xray unremarkable. No trop leak. EKG sinus rhythm with RBBB, rate 78, QTC 437. 4 baby aspirin and sublingual nitro given in ED with relief in chest pain.  1/29/22: 81-year-old male with coronary artery disease status post CABG and PCIs, peripheral vascular disease status post intervention presented with left-sided chest pain while shoveling snow, improved with sublingual nitroglycerin in the emergency room.  Patient elevated troponin with no ischemic EKG changes.  Patient admitted for non STEMI, started on heparin GTT Cardiology was consulted patient underwent coronary angiogram with the intervention including stents.  Patient retroperitoneal hemorrhage following the procedure, hypotensive and anemic requiring blood transfusion.  Peripheral angiogram did not reveal pseudoaneurysm or extravasation.  Hemoglobin remained stable.  Patient was supposed to be on warfarin for DVT, repeat lower extremity ultrasound showed no deep vein thrombosis and in the setting of retroperitoneal hemorrhage with anemia, dual anti-platelet it was deemed patient is at significant risk for bleeding and anticoagulation discontinued.  Patient had recurrence of symptoms IVC filter can be considered as an outpatient.  On discharge patient was afebrile and hemodynamically stable he was discharged home.
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: Troponin increased, Ultrasound Doppler normal
Clinical narrative: Pfizer Dose 1 3/8/21 (EN6199) Pfizer Dose 2 4/7/21 (ER8737) Pfizer Dose 3 10/21/21 (FF2593) COVID Positive 1/11/22 COVID Positive 1/24/22  1/24/22: Patient is a 81 year old male who presented to ED via EMS with complaints of chest pain while shoveling snow just prior to arrival. He took 2 sublingual nitro with no relief in symptoms and called EMS. Chest pain was left sided, non-radiating, sharp and constant in nature, no alleviating or aggravating factors. Denies shortness of breath. No diaphoresis, nausea, or vomiting. Chest pain relieved in ED. He is fully vaccinated for Covid-19. Past has a past medical history of hypertension, hyperlipidemia, hypothyroidism, CAD s/p CABG and multiple stents, type 2 diabetes mellitus, seizure disorder, pvd s/p stent, anemia, right lower extremity DVT on Coumadin and history of cva.  On arrival to ED pt was hypertensive 165/65. Labs significant for hyperglycemia 266. Hypomagnesemia 1.3. D-dimer 0.65. CT chest no PE. Chest xray unremarkable. No trop leak. EKG sinus rhythm with RBBB, rate 78, QTC 437. 4 baby aspirin and sublingual nitro given in ED with relief in chest pain.  1/29/22: 81-year-old male with coronary artery disease status post CABG and PCIs, peripheral vascular disease status post intervention presented with left-sided chest pain while shoveling snow, improved with sublingual nitroglycerin in the emergency room.  Patient elevated troponin with no ischemic EKG changes.  Patient admitted for non STEMI, started on heparin GTT Cardiology was consulted patient underwent coronary angiogram with the intervention including stents.  Patient retroperitoneal hemorrhage following the procedure, hypotensive and anemic requiring blood transfusion.  Peripheral angiogram did not reveal pseudoaneurysm or extravasation.  Hemoglobin remained stable.  Patient was supposed to be on warfarin for DVT, repeat lower extremity ultrasound showed no deep vein thrombosis and in the setting of retroperitoneal hemorrhage with anemia, dual anti-platelet it was deemed patient is at significant risk for bleeding and anticoagulation discontinued.  Patient had recurrence of symptoms IVC filter can be considered as an outpatient.  On discharge patient was afebrile and hemodynamically stable he was discharged home.
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, COVID-19, Chest X-ray normal, Computerised tomogram head normal, Decreased appetite
Clinical narrative: Moderna Dose 1 3/9/21 (003A21A) Moderna Dose 2 4/13/21 (026B21A) COVID Positive 1/16/22  1/17/22: 81-year-old male with history of TIA, seizure with Todd's paralysis, AAA, hypertension, hyperlipidemia and right internal carotid artery stenosis presented with generalized weakness.  Patient reports symptoms started about 3 days ago with generalized weakness, poor appetite and unsteady gait.  Patient reports symptoms have been getting progressively worse as he became increasingly weak having difficulty walking, denies any loss of sensation in his extremities, no facial droop or speech abnormalities. No back pain no recent trauma no abdominal pain, nausea or vomiting.  Denies any UTI symptoms.  Patient is a febrile and hemodynamically stable.  Unremarkable CMP, troponin less than 0.01, WBC 14.6 with hemoglobin of 13.7.  Chest x-ray is unremarkable for acute abnormalities.  Head CT is unremarkable for acute abnormalities.  Urinalysis and COVID-19 PCR pending.  1/20/22: P.o. vitamin-C, vitamin-D and zinc sulfate  P.o. aspirin 81 mg daily  Resume home Keppra 1000 mg b.i.d.  Hemodynamically stable for discharge  Will discharge home with services  Patient and wife agree with plan of care  Follow-up with PCP in 3-5 days
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: Gait disturbance, Haemoglobin decreased, Metabolic function test normal, Pyrexia, SARS-CoV-2 test
Clinical narrative: Moderna Dose 1 3/9/21 (003A21A) Moderna Dose 2 4/13/21 (026B21A) COVID Positive 1/16/22  1/17/22: 81-year-old male with history of TIA, seizure with Todd's paralysis, AAA, hypertension, hyperlipidemia and right internal carotid artery stenosis presented with generalized weakness.  Patient reports symptoms started about 3 days ago with generalized weakness, poor appetite and unsteady gait.  Patient reports symptoms have been getting progressively worse as he became increasingly weak having difficulty walking, denies any loss of sensation in his extremities, no facial droop or speech abnormalities. No back pain no recent trauma no abdominal pain, nausea or vomiting.  Denies any UTI symptoms.  Patient is a febrile and hemodynamically stable.  Unremarkable CMP, troponin less than 0.01, WBC 14.6 with hemoglobin of 13.7.  Chest x-ray is unremarkable for acute abnormalities.  Head CT is unremarkable for acute abnormalities.  Urinalysis and COVID-19 PCR pending.  1/20/22: P.o. vitamin-C, vitamin-D and zinc sulfate  P.o. aspirin 81 mg daily  Resume home Keppra 1000 mg b.i.d.  Hemodynamically stable for discharge  Will discharge home with services  Patient and wife agree with plan of care  Follow-up with PCP in 3-5 days
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: SARS-CoV-2 test positive, Troponin normal, Urine analysis, White blood cell count increased
Clinical narrative: Moderna Dose 1 3/9/21 (003A21A) Moderna Dose 2 4/13/21 (026B21A) COVID Positive 1/16/22  1/17/22: 81-year-old male with history of TIA, seizure with Todd's paralysis, AAA, hypertension, hyperlipidemia and right internal carotid artery stenosis presented with generalized weakness.  Patient reports symptoms started about 3 days ago with generalized weakness, poor appetite and unsteady gait.  Patient reports symptoms have been getting progressively worse as he became increasingly weak having difficulty walking, denies any loss of sensation in his extremities, no facial droop or speech abnormalities. No back pain no recent trauma no abdominal pain, nausea or vomiting.  Denies any UTI symptoms.  Patient is a febrile and hemodynamically stable.  Unremarkable CMP, troponin less than 0.01, WBC 14.6 with hemoglobin of 13.7.  Chest x-ray is unremarkable for acute abnormalities.  Head CT is unremarkable for acute abnormalities.  Urinalysis and COVID-19 PCR pending.  1/20/22: P.o. vitamin-C, vitamin-D and zinc sulfate  P.o. aspirin 81 mg daily  Resume home Keppra 1000 mg b.i.d.  Hemodynamically stable for discharge  Will discharge home with services  Patient and wife agree with plan of care  Follow-up with PCP in 3-5 days
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Inappropriate schedule of product administration, SARS-CoV-2 test positive
Clinical narrative: Moderna 2/5/21, 3/8/21, 10/22/21. Positive on 7/3/22
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: Moderna 1/11/21, 2/4/21. Positive on 6/22/22
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: Moderna 4/8/21, 5/5/21. Positive on 7/3/22
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: Moderna 2/5/21, 3/5/21. Positive on 7/3/22
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Urticaria
Clinical narrative: Hives for 36 hours
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: Janssen 3/8/21, Pfizer 11/8/21. Positive on 7/5/22
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Inappropriate schedule of product administration, SARS-CoV-2 test positive
Clinical narrative: Pfizer 12/23/20, 2/3/21, 12/21/21. Positive on 7/5/22
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Malaise, SARS-CoV-2 test positive
Clinical narrative: About 7:00 pm, on June 5, 2022, I was not feeling well and I went to bed.  I woke at 3:00 am and my temperature was 99.5.  Immediately thought I should do a home COVID-19 test and it was positive. I messaged my doctor and asked if I needed a PCR and he said no. I tested myself every day until I was negative, on June 8, 2022. He prescribed Paxlovid.
Age: 6.0
Sex: M
Vaccine: COVID19
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: Received dose inappropriate for age
Age: 66.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Cough, Nasal congestion, Respiratory tract congestion, SARS-CoV-2 test positive
Clinical narrative: I did not have an adverse reaction to the vaccine but I did contract COVID-19. Test positive on June 30.  I had a stuffy nose, congestion and a dry cough.  I went to see my doctor and he didn't think I needed a prescription. I took over-the-counter cold medication for my symptoms.
Age: 85.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Atrial fibrillation, COVID-19, Condition aggravated, Cough
Clinical narrative: Discharge Provider: MD Primary Care Provider at Discharge: DO Admission Date: 6/22/2022 Discharge Date: 06/25/2022  Chief Complaint Patient presents with ? COUGH     Positive COVID via home test today. Family concerned because they stated he had a reading of 78% O's on room air. EMS stated he was 98 for them, without intervention or s/s of distress.    Patient is an 85-year-old man with a past medical history of atrial fibrillation on anticoagulation, multiple cardiac elements, type 2 diabetes mellitus, and vascular dementia who was admitted to Hospital on June 22, 2022 for weakness associated with COVID-19 infection.  Upon his arrival patient had stable vital signs.  He was physically deconditioned and work with physical therapy and occupational therapy.  Upon the recommendation the patient will be receiving home health care services including physical therapy and occupational therapy.   The patient did test positive for COVID-19.  It is unclear the duration of his symptoms and his vaccination status.  He is not a candidate for Decadron or remdesivir as he was never hypoxic.  He received supportive care with Tylenol and cough suppressant.   During patient's hospitalization he did have 1 episode of atrial fibrillation with rapid ventricular rates.  He did receive IV Lopressor with good response.  The patient's home medications including digoxin and metoprolol were resumed and his rates have remained controlled for greater than 24 hours.  He will be discharged home with continuation of his home medications in stable condition.
Age: 85.0
Sex: M
Vaccine: COVID19
Symptoms: Physical deconditioning, SARS-CoV-2 test positive
Clinical narrative: Discharge Provider: MD Primary Care Provider at Discharge: DO Admission Date: 6/22/2022 Discharge Date: 06/25/2022  Chief Complaint Patient presents with ? COUGH     Positive COVID via home test today. Family concerned because they stated he had a reading of 78% O's on room air. EMS stated he was 98 for them, without intervention or s/s of distress.    Patient is an 85-year-old man with a past medical history of atrial fibrillation on anticoagulation, multiple cardiac elements, type 2 diabetes mellitus, and vascular dementia who was admitted to Hospital on June 22, 2022 for weakness associated with COVID-19 infection.  Upon his arrival patient had stable vital signs.  He was physically deconditioned and work with physical therapy and occupational therapy.  Upon the recommendation the patient will be receiving home health care services including physical therapy and occupational therapy.   The patient did test positive for COVID-19.  It is unclear the duration of his symptoms and his vaccination status.  He is not a candidate for Decadron or remdesivir as he was never hypoxic.  He received supportive care with Tylenol and cough suppressant.   During patient's hospitalization he did have 1 episode of atrial fibrillation with rapid ventricular rates.  He did receive IV Lopressor with good response.  The patient's home medications including digoxin and metoprolol were resumed and his rates have remained controlled for greater than 24 hours.  He will be discharged home with continuation of his home medications in stable condition.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: hospitalization with covid; fully vaccinated with booster